Program
nipocalimab
Also written as “Nipocalimab” and “M281”.
Its studies are mostly in Myasthenia Gravis · Sjogren's Syndrome · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Myositis, led by Johnson & Johnson.
Furthest: phase 3, since Sep 18, 201924 company-led studies, 11 open or runningNext primary completion: Dec 15, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 2411 open or running | phase 3since Sep 18, 2019 | Jun 14, 2016 | Dec 15, 2026phase 3 · NCT05327114 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jun 14, 2016.
- Jul 13, 2021Phase 1 study in HealthyNCT04973566 · 48 enrolled · Netherlands
- Aug 2, 2021Phase 2 study in Arthritis, RheumatoidNCT04991753 · 53 enrolled · United States, Germany, Poland and more
- Dec 7, 2021Phase 1 study in HealthyNCT05151692 · 30 enrolled · China
- Feb 22, 2022Phase 3 study in Myasthenia GravisNCT05265273 · 12 planned · United States, Japan, Netherlands and more
- Apr 7, 2022Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114 · 201 planned · United States, Argentina, Australia and more
- May 17, 2022Phase 2 study in MyositisNCT05379634 · 36 enrolled · United States, Canada, Czechia and more
- Jun 13, 2023Phase 3 study in Hemolytic Disease of the Fetus and NewbornNCT05912517 · 120 planned · United States, Argentina, Australia and more
- Sep 1, 2023Phase 2 study in Arthritis, RheumatoidNCT06028438 · 103 enrolled · United States, Argentina, Germany and more
- Jun 4, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06449651 · 39 planned · Belgium, Brazil, France and more
- Jul 30, 2024Phase 3 study in Thrombocytopenia, Neonatal AlloimmuneNCT06533098 · 50 planned · United States, Austria, Belgium and more
- Dec 18, 2024Phase 3 study in Sjogren's SyndromeNCT06741969 · 655 enrolled · United States, Argentina, Austria and more
- Oct 15, 2025Phase 3 study in Myasthenia GravisNCT07217587 · 115 planned · United States, Germany, Israel and more
- Feb 23, 2026Phase 3 study in Lupus Erythematosus, SystemicNCT07438496 · 600 planned · United States, Argentina, Australia and more
- Jun 22, 2026Phase 1 study in HealthyNCT07669077 · 8 planned · United States
Ahead
- Dec 15, 2026Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT05327114
- Feb 4, 2027Primary completion: phase 3 study in Sjogren's SyndromeNCT06741969
- Feb 16, 2027Primary completion: phase 1 study in HealthyNCT07669077
- Jun 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT05265273
TargetBeta
FCGRT →read by rule
“IgG receptor FcRn large subunit p51 antagonist”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 48 |
| rozanolixizumabrule | UCB | phase 4 | 23 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07669077Healthy · United States | 1 | Recruiting | Feb 16, 2027 | 8 |
| NCT07438496Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Dec 6, 2028 | 600 |
| NCT07217587Myasthenia Gravis · United States, Germany, Israel and more | 3 | Recruiting | Sep 28, 2027 | 115 |
| NCT06741969Sjogren's Syndrome · United States, Argentina, Austria and more | 3 | Active, not recruiting | Feb 4, 2027 | 655 |
| NCT06533098Thrombocytopenia, Neonatal Alloimmune · United States, Austria, Belgium and more | 3 | Recruiting | Dec 15, 2027 | 50 |
| NCT06449651Thrombocytopenia, Neonatal Alloimmune · Belgium, Brazil, France and more | 3 | Recruiting | Dec 5, 2029 | 39 |
| NCT06028438Arthritis, Rheumatoid · United States, Argentina, Germany and more | 2 | Completed | Aug 29, 2024 | 103 |
| NCT05912517Hemolytic Disease of the Fetus and Newborn · United States, Argentina, Australia and more | 3 | Recruiting | Aug 5, 2027 | 120 |
| NCT05379634Myositis · United States, Canada, Czechia and more | 2 | Completed | Sep 4, 2025 | 36 |
| NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more | 3 | Recruiting | Dec 15, 2026 | 201 |
| NCT05265273Myasthenia Gravis · United States, Japan, Netherlands and more | 3 | Recruiting | Jun 30, 2027 | 12 |
| NCT05151692Healthy · China | 1 | Completed | Sep 9, 2022 | 30 |
| NCT04991753Arthritis, Rheumatoid · United States, Germany, Poland and more | 2 | Completed | Aug 10, 2022 | 53 |
| NCT04973566Healthy · Netherlands | 1 | Completed | May 27, 2022 | 48 |
| NCT04968912Sjogren's Syndrome · United States, France, Germany and more | 2 | Completed | Oct 23, 2023 | 163 |
| NCT04951622Myasthenia Gravis · United States, Australia, Belgium and more | 3 | Recruiting | Nov 17, 2023 | 199 |
| NCT04883619Lupus Nephritis | 2 | Withdrawn | Feb 28, 2028 | 0 |
| NCT04882878Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more | 2 | Completed | Apr 30, 2024 | 228 |
| NCT04848558Healthy · Netherlands | 1 | Completed | May 26, 2022 | 89 |
| NCT04119050Warm Autoimmune Hemolytic Anemia · United States, Brazil, China and more | 3 | Active, not recruiting | Feb 2, 2025 | 118 |
| NCT03896295Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Terminated | Dec 9, 2020 | 37 |
| NCT03842189Hemolytic Disease of the Fetus and Newborn · United States, Australia, Belgium and more | 2 | Completed | Aug 5, 2024 | 25 |
| NCT03772587Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Jun 25, 2020 | 68 |
| NCT02828046Healthy Volunteers · Netherlands | 1 | Completed | Aug 8, 2017 | 50 |
How it is read
Names in the registry
- “Nipocalimab”, 19 entries
- “M281”, 5 entries
Conditions, from the studies’ own filings
- Myasthenia Gravis, 5 studies
- Sjogren's Syndrome, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Myositis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.